TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34651171
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) hydration
Study: 35264347
Drug: TUS-guided pigtail
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUS-guided pigtail catheter placement and intrapleural therapy with Actilyse and DNase
Study: 36130946
Drug: Neflamapimod 40
Normalized name: Neflamapimod
DrugBank: Neflamapimod (DB07138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neflamapimod 40 mg
Study: 35063281
Drug: Paclitaxel 80mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 80mg/m2 weekly up to 24 weeks (control)
Study: 35063281
Drug: Olaparib 300mg
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg tablets twice daily + Cediranib 20mg daily (continuous schedule)
Study: 35063281
Drug: Olaparib 300mg
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300mg tablets twice daily + Cediranib 20mg 5 days/week (intermittent schedule)
Study: 35358464
Drug: Isatuximab plus
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Isatuximab plus pomalidomide and low-dose dexamethasone
Study: 35151415
Drug: Pomalidomide and
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide and low-dose dexamethasone (Control)
Study: 34506761
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m2) plus uromitexan (200 mg/m2) at days 0, 15, 30, and 60
Study: 35940560
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) 3g administered intra-articular after cementation and prior to capsular closure
Study: 35075022
Drug: Single-shot caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot caudal morphine
Study: 35075022
Drug: Intravenous narcotic-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous narcotic-based anesthesia
Study: 34454540
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine 300 mg once-daily for 14 days in repeated 28-day cycles
Study: 34454540
Drug: Oral azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral azacitidine
Study: 36896702
Drug: HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 vaccine
Study: 35105495
Drug: HBV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV vaccine
Study: 36326299
Drug: Sour cherry
Normalized name: SOUR CHERRY
DrugBank: Sour cherry (DB10630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sour cherry concentrate (75 ml twice daily for 2 weeks)
Study: 32681461
Drug: ASP3652 (1–600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (1–600 mg single dose)
Study: 32681461
Drug: ASP3652 (10–300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (10–300 mg bid and 600 mg qd for 14 days)
Study: 32681461
Drug: ASP3652 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (single and multiple doses)
Study: 32681461
Drug: ASP3652 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (multiple doses)
Study: 32681461
Drug: ASP3652 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP3652 (single dose with food)
Study: 35674613
Drug: T. harzianum
Approvals — FDA: no, EMA: no, PMDA: no
Description: T. harzianum with 50 g of NPK treatment (T2)
Study: 35674613
Drug: B. thuringiensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. thuringiensis plus 50 g NPK treatment (T3)
Study: 35674613
Drug: B. thuringiensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. thuringiensis with 25 g NPK fertilizer treatment (T5)
Study: 35333363
Drug: Attainment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attainment of multiple treatment targets
Study: 33908296
Drug: 250 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 µg roflumilast
Study: 33908296
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg roflumilast
Study: 35766037
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of candesartan and carvedilol plus standard of care
Study: 35988057
Drug: EPI-589 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-589 (500 mg twice daily)
Study: 35988057
Drug: EPI-589 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-589 (750 mg twice daily)
Study: 35988057
Drug: EPI-589 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-589 (1000 mg single daily dose)
Study: 35988057
Drug: EPI-589 (250-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI-589 (250-1000 mg single doses)
Study: 34742669
Drug: Group Intervention
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Intervention in OBEsity (IGOBE) program with weekly sessions for six weeks
Study: 34742669
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care therapy (Control Group)
Study: 34550930
Drug: Subglandular breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subglandular breast augmentation
Study: 32736592
Drug: EDP1815 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 (2 capsules twice daily for up to 7 days, with an option to extend to 14 days)
Study: 32736592
Drug: Dapagliflozin (10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10mg once daily) and Ambrisentan (5mg once daily for up to 14 days)
Study: 35385557
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) 0.2 mg before general anesthesia
Study: 33108123
Drug: Jiawei Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiawei Xiaoyao (JX) pill (12 g/d, 6 g twice a day) for 4 weeks
Study: 33108123
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 g/d, 6 g twice a day) for 4 weeks
Study: 33108123
Drug: Jiawei Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiawei Xiaoyao (JX) pill
Study: 34753557
Drug: RAS blockers
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blockers (monotherapy or dual blockade)
Study: 34753557
Drug: Baseline IL-6
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IL-6 levels > 4.84 pg/mL
Study: 34753557
Drug: RAS blockade
Normalized name: RAS
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAS blockade (monotherapy or dual blockade)
Study: 33600437
Drug: Intraplexus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraplexus injection of 25mL ropivacaine 0.5% between C5‐C6 nerve roots
Study: 33600437
Drug: Extraplexus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraplexus injection of 25mL ropivacaine 0.5% anterior and posterior to the brachial plexus
Study: 33243209
Drug: Melatonin 1
Normalized name: melatonin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 1 mg/morning and 3 mg/at bedtime (Group IIIb)
Study: 36036539
Drug: Efgartigimod (FcRn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efgartigimod (FcRn antagonist)
Study: 36483622
Drug: Ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor loading dose (LD)
Study: 33029267
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml methylene blue
Study: 33029267
Drug: 3.5 ml
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 ml methylene blue
Study: 33029267
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml methylene blue
Study: 33029267
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml methylene blue
Study: 35568804
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with clopidogrel plus aspirin
Study: 33551196
Drug: Dasatinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles)
Study: 32175587
Drug: Survey responders
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Survey responders in the intervention group who previously reported non-vaccine use
Study: 34210347
Drug: Combined tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined tDCS and VR-based therapy (30 minutes each)
Study: 34210347
Drug: Combined tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined tDCS and VR-based therapy
Study: 36190145
Drug: Two short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two short implants (6 mm) with single-unit restorations (group TWO)
Study: 36190145
Drug: One single
Normalized name: Risperidone Single-Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single short implant (6 mm) with a cantilever restoration (group ONE-C)
Study: 36190145
Drug: Implants that
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants that survived
Study: 32112126
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia and a continuous intraarticular catheter with ropivacaine (group L)
Study: 32474816
Drug: Adjuvant capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjuvant capecitabine chemotherapy
Study: 35858154
Drug: Oral Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Paclitaxel plus Encequidar (oPac + E) 205 mg/m2 paclitaxel plus 15 mg E, 3 consecutive days per week
Study: 35858154
Drug: Intravenous Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Paclitaxel (IVpac) 175 mg/m2 once every 3 weeks
Study: 35858154
Drug: Oral Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Paclitaxel plus Encequidar (oPac + E)
Study: 35858154
Drug: Intravenous Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Paclitaxel (IVpac)
Study: 32959110
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of ASA administered in the evening (n = 56)
Study: 32959110
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of ASA administered in the morning (n = 58)
Study: 36038163
Drug: Lobe-specific lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobe-specific lymph node dissection (L-SLND)
Study: 34964825
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection (US)
Study: 34964825
Drug: Freehand injection
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Freehand injection (FH)
Study: 32649717
Drug: Intravenous hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydromorphone (IVH)
Study: 35564858
Drug: Control (activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (activities of daily living)
Study: 32700798
Drug: S-Praziquantel (S-PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: S-Praziquantel (S-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Study: 32700798
Drug: R-Praziquantel (R-PZQ)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R-Praziquantel (R-PZQ) with ketoconazole (KTZ) as a CYP3A inhibitor
Study: 32479166
Drug: Rituximab infusion
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusion
Study: 35412448
Drug: Interocclusal splint
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interocclusal splint therapy, diclofenac, and TMJ mobilization
Study: 32568867
Drug: Entecavir monotherapy
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir monotherapy (n = 70)
Study: 32568867
Drug: Entecavir add-on
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir add-on peg-interferon therapy (n = 74)
Study: 32568867
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (monotherapy and combination therapy)
Study: 35804307
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (cisplatin and 5-fluorouracil plus radiotherapy followed by surgical resection)
Study: 35804307
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy following surgical resection)
Study: 34916645
Drug: Non-surgical peri-implantitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical peri-implantitis treatment combined with systemic antimicrobials
Study: 34916645
Drug: Full mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full mouth non-surgical peri-implantitis treatment
Study: 35560305
Drug: High Sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Sodium (HS) diet (6,900 mg/day) with Placebo (PL)
Study: 35560305
Drug: High Sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Sodium (HS) diet (6,900 mg/day) with Antioxidants (AO)
Study: 35560305
Drug: Low Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Sodium (LS) diet (2,300 mg/day) with Placebo (PL)
Study: 35560305
Drug: Low Sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Sodium (LS) diet (2,300 mg/day) with Antioxidants (AO)
Study: 34438029
Drug: SZL (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SZL (3.2 g/d)
Study: 34438029
Drug: FLX (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLX (20 mg/d)
Study: 34918639
Drug: Bismuth potassium
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth potassium citrate capsules (220 mg)
Study: 34918639
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth pectin capsules (200 mg)
Study: 34918639
Drug: Bismuth pectin
Normalized name: bismuth / pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth pectin granules (150 mg)
Study: 34918639
Drug: Bismuth pectin
Normalized name: bismuth / pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth pectin granules (300 mg)
Study: 32563609
Drug: Low-dosage sIPV
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage sIPV
Study: 32563609
Drug: Medium-dosage sIPV
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dosage sIPV
Study: 32563609
Drug: High-dosage sIPV
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage sIPV
Study: 33414503
Drug: CPAP (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP (Continuous Positive Airway Pressure) treatment
Study: 32370818
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg/tab daily
Study: 32370818
Drug: moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moclobemide 150 mg/tab daily
Study: 32316129
Drug: Passiflora setacea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passiflora setacea juice (250 mL)
Study: 36241898
Drug: Low-volume high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume high-intensity interval training (HIIT), 12 weeks, 3 times weekly on a rowing ergometer, average power output of 138 W
Study: 32807632
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) with aerobic exercise plus usual care (UC)
Study: 32095843
Drug: Prilocaine +
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine + Tramadol 1 mg/kg (P + T1)
Study: 32095843
Drug: Prilocaine +
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine + Tramadol 2 mg/kg (P + T2)
Study: 32095843
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (Control group)
Study: 34554649
Drug: Home-based aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based aerobic exercise at 40-60% peak heart rate thrice weekly and resistance training at 70% of one-repetition maximum twice weekly for 6 months
Study: 36138535
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of TXA (2 g bolus within 45 minutes of injury)
Study: 36138535
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of TXA (1 g bolus plus 1 g 8 h infusion after 45 minutes of injury)
Study: 32457012
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg intravenous)
Study: 36231604
Drug: Neurorehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurorehabilitation treatment plus ultrasound-guided dry needling
Study: 36231604
Drug: Neurorehabilitation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurorehabilitation treatment
Study: 33961812
Drug: Sit-to-stand exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand exercises and protein-rich nutritional supplements (12-week intervention)
Study: 33961812
Drug: Sit-to-stand exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit-to-stand exercises and protein-rich nutritional supplements
Study: 32460618
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) therapy using low energy, nonionizing light primarily in the visible or near-infrared spectrum.
Study: 32205155
Drug: Normothermia and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia and early treatment of fever (≥37.8 °C)
Study: 35180099
Drug: Graston Technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graston Technique (GT) combined with Conventional Physical Therapy (CPT)
Study: 35419831
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with S‐1 (CCRT)
Study: 32139204
Drug: IV chlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV chlorpheniramine (CPM), IV dexamethasone (CPM/Dex), and oral prednisolone for 5 days (CPM/Dex/Pred)
Study: 36281627
Drug: Mexiletine (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (333 mg oral dose)
Study: 33248918
Drug: Intraarterial BMSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial BMSC injection (group B)
Study: 33248918
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (group A)
Study: 36456477
Drug: Cervical injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical injection group (1 ml of nano-carbon injected at 3 and 9 o'clock in the cervix)
Study: 36456477
Drug: Uterine injection
Normalized name: ETHIODIZED OIL 480 mg in 1 mL INTRAUTERINE INJECTION [LIPIODOL]
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uterine injection group (4 ml of methylene blue injected into the uterine body at 2 sites)
Study: 36456477
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection group (1 ml of nano-carbon + 4 ml of methylene blue)
Study: 32682370
Drug: Tremelimumab (anti-CTLA-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (anti-CTLA-4 antibody)
Study: 34709010
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.25 µg/kg/h)
Study: 34709010
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 µg/kg and maintenance dose 0.5 µg/kg/h)
Study: 33106028
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (single injection, with or without ultrasound guidance)
Study: 33106028
Drug: Second corticosteroid
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second corticosteroid injection
Study: 33106028
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (across all groups)
Study: 36317442
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg daily for 40 days
Study: 32046865
Drug: Serum PTH
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PTH levels < 2.9 pmol/L measured 1 hour after surgery and on the first postoperative day
Study: 32046865
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of calcium supplements
Study: 36235798
Drug: Psyllium (fiber‐matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (fiber‐matched, 7.5 g/day)